Clinical and Translational Allergy | |
Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells | |
Lanny J Rosenwasser1  Abby L Dotson2  Nicole M Gigliotti1  Marcia A Chan1  | |
[1] Department of Pediatrics, Division of Immunology Research, Children’s Mercy Hospitals & Clinics, Kansas City, MO 64108, USA;Department of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA | |
关键词: Human B cells; IgE; Anti-IgE; | |
Others : 794216 DOI : 10.1186/2045-7022-3-29 |
|
received in 2013-05-07, accepted in 2013-08-27, 发布年份 2013 | |
【 摘 要 】
Background
Omalizumab, is a humanized anti-IgE monoclonal antibody used to treat allergic asthma. Decreased serum IgE levels, lower eosinophil and B cell counts have been noted as a result of treatment. In vitro studies and animal models support the hypothesis that omalizumab inhibits IgE synthesis by B cells and causes elimination of IgE-expressing cells either by induction of apoptosis or induction of anergy or tolerance.
Methods
We examined the influence of omalizumab on human tonsillar B cell survival and on the genes involved in IgE synthesis. Tonsillar B cells were stimulated with IL-4 plus anti-CD40 antibody to induce class switch recombination to IgE production in the presence or absence of omalizumab. Cell viability was assessed and RNA extracted to examine specific genes involved in IgE synthesis.
Conclusions
We found that omalizumab reduced viable cell numbers but this was not through induction of apoptosis. IL-4R and germline Cϵ mRNA levels were decreased as well as the number of membrane IgE+ cells in B cells treated with omalizumab. These data suggest that omalizumab may decrease IgE synthesis by human B cells by specifically targeting membrane IgE-bearing B cells and inducing a state of anergy.
【 授权许可】
2013 Chan et al.; licensee BioMed Central Ltd.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20140705063801173.pdf | 893KB | download | |
Figure 6. | 75KB | Image | download |
Figure 5. | 79KB | Image | download |
Figure 4. | 68KB | Image | download |
Figure 3. | 60KB | Image | download |
Figure 2. | 53KB | Image | download |
Figure 1. | 83KB | Image | download |
【 图 表 】
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.
【 参考文献 】
- [1]Platts-Mills TA: The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001, 164:S1-S5.
- [2]Chang TW: The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000, 18:157-162.
- [3]Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108:184-190.
- [4]Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD: The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005, 60:302-308.
- [5]Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K: Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
- [6]Hanf G, Brachmann I, Kleine-Tebbe J, Seybold J, Kunkel G, Suttorp N, Noga O: Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. Allergy 2006, 61:1141-1144.
- [7]Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, Kunkel G, Suttorp N, Seybold J: Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2007, 117:1493-1499.
- [8]Djukanović R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Weibin B, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV: Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004, 170:583-593.
- [9]Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Ädelroth E, Gustafsson H, Sandström T, Rak S: The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002, 110:68-71.
- [10]Infűhr D, Crameri R, Lamers R, Achatz G: Molecular and cellular targets of anti-IgE antibodies. Allergy 2005, 60:977-985.
- [11]Geha RS, Jabara HH, Brodeur SR: The regulation of immunoglobulin E class-switch recombination. Nat Rev Immunol 2003, 3:721-732.
- [12]Gauchat JF, Lebman DA, Coffman RL, Gascan H, de Vries JE: Structure and expression of germline ϵ transcripts in human B cells induced by interleukin 4 to switch to IgE production. J Exp Med 1990, 172:463-473.
- [13]Teague RM, Harlan LM, Benedict SH, Chan MA: MIP-1α induces differential MAP kinase activation and IκB gene expression in human B lymphocytes. J Interferon Cytokine Res 2004, 24:403-410.
- [14]Jeppson JD, Patel HR, Sakata N, Domenico J, Terada N, Gelfand EW: Requirement for dual signals by anti-CD40 and IL-4 for the induction of nuclear factor-κB, IL-6, and IgE in human B lymphocytes. J Immunol 1998, 161:1738-1742.
- [15]Roth M, Tamm M: The effects of omalizumab on IgE-induced cytokine synthesis by asthmatic airway smooth muscle cells. Ann Allergy Asthma Immunol 2010, 104:152-160.
- [16]Gomez G, Jogie-Brahim S, Shima M, Schwartz LB: Omalizumab reverses the phenotype and functional effects of IgE-enhanced FcϵRI on human skin mast cells. J Immunol 2007, 179:1353-1361.
- [17]Ogata H, Ford D, Kouttab N, King TC, Vita N, Minty A, Stoeckler J, Morgan D, Grasole C, Morgan JW: Regulation of interleukin-13 receptor constituents on mature human B lymphocytes. J Biol Chem 1998, 273:9864-9871.
- [18]Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE: The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999, 17:701-738.
- [19]Conrad DH, Ford JW, Sturgill JL, Gibb DR: CD23: an overlooked regulator of allergic disease. Curr Allergy Asthma Rep 2007, 7:331-337.
- [20]Cooper AM, Hobson PS, Jutton MR, Kao MW, Drung B, Schmidt B, Fear DJ, Beavil AJ, McDonnell JM, Sutton BJ, Gould HJ: Soluble CD23 controls IgE synthesis and homeostasis in human B cells. J Immunol 2012, 188:3199-3207.
- [21]Chan MA, Gigliotti NM, Matangkasombut P, Gauld SB, Cambier JC, Rosenwasser LJ: CD23-mediated cell signaling in human B cells differs from signaling in cells of the monocytic lineage. Clin Immunol 2012, 137:330-336.
- [22]Yokota A, Kikutani H, Tanaka T, Sato R, Barsumian EL, Suemura M, Kishimoto T: Two species of human Fcϵ receptor II (FcϵRII/CD23): tissue-specific and IL-4-specific regulation of gene expression. Cell 1998, 55:611-618.
- [23]Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N: Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2009, 91:154-159.
- [24]Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, McAlary M, Fowler-Taylor A, Racine A, Gupta N, Fick R, Della Cioppa G: Omalizumab Seasonal Allergic Rhinitis Trail Group: effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001, 286:2956-2967.
- [25]Noga O, Hanf G, Kunkel G, Kleine-Tebbe J: Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol 2008, 2008(146):66-70.
- [26]Noga O, Habf G, Kunkel G: Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003, 131:46-52.
- [27]Eray M, Tuomiloski T, Wu H, Nordstrom T, Andersson LC, Knuutila S, Kaartinen M: Cross-linking of surface IgG induces apoptosis in a bcl-2 expressing human follicular lymphoma line of mature B cell phenotype. Int Immunol 1994, 6:1817-1827.
- [28]Warner GL, Scott DW: A polyclonal model of B cell tolerance. I Fc-dependent and Fc-independent induction of nonresponsiveness by pretreatment of normal splenic B cells with anti-Ig. J Immunol 1991, 146:2185-2191.
- [29]Fulcher DA, Basten A: Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med 1994, 179:125-134.
- [30]Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, Holgate S: Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007, 101:1483-1492.
- [31]Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P: The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med 2009, 103:1098-1113.